People reaching for over-the-counter joint-pain capsules at major retailers have unknowingly swallowed prescription-strength steroids and anti-inflammatory drugs, according to laboratory findings from the U.S. Food and Drug Administration. The agency’s testing confirmed that products including Artri King, Curcuflex, Yeicob Acido Hialuronico, and RM Joe contained undeclared dexamethasone and diclofenac, two prescription pharmaceuticals never listed on their labels. More than 30 consumers reported serious health effects from Artri and Ortiga products alone, and peer-reviewed case reports have linked the supplements to Cushing syndrome, adrenal insufficiency, and hip fracture.
Hidden steroids in arthritis supplements and the real-world harm
The core danger is straightforward: consumers who believe they are taking a natural supplement are instead ingesting corticosteroids that can suppress the adrenal glands, weaken bones, and trigger metabolic disorders. FDA laboratory analysis confirmed that Artri King contains dexamethasone, a potent corticosteroid, along with diclofenac, a nonsteroidal anti-inflammatory drug available in the United States only by prescription. The same combination appeared in Curcuflex, another supplement marketed for arthritis relief, where FDA testing also found undeclared steroids and NSAIDs.
These are not trace contaminants. Dexamethasone is roughly 25 times more potent than cortisol, and prolonged use without medical supervision can cause weight gain, elevated blood sugar, immune suppression, and bone loss. Stopping abruptly is also dangerous: the body’s own cortisol production can shut down during extended steroid exposure, meaning sudden withdrawal may cause adrenal crisis, a potentially life-threatening condition. The FDA’s own consumer guidance on these products warns people not to stop taking them without first consulting a health professional, an unusual step that signals the agency recognizes patients may already be physically dependent on a supplement they never knew contained a drug.
Diclofenac, the hidden NSAID identified in these supplements, carries its own risks. At prescription doses, the drug is associated with gastrointestinal bleeding, kidney injury, and elevated cardiovascular risk, especially when used chronically or in people with underlying heart disease. When consumers unknowingly combine a diclofenac-laced supplement with other over-the-counter pain relievers, they may be stacking multiple NSAIDs without realizing it, increasing the chance of serious side effects.
A hypothesis worth examining is whether the volume of FDA import alerts and retailer warning letters for hidden-steroid supplements tracks with spikes in endocrine-related hospital admissions at safety-net facilities in the same regions. No public dataset currently connects those two data streams in a way that would confirm or reject the pattern. But the clinical literature already documents the downstream harm. A case series published in a peer-reviewed medical journal described adrenal insufficiency among joint-replacement patients at a safety-net hospital who reported using Artri King and related supplements. A separate case report in the Journal of the American College of Emergency Physicians Open linked Artri Ajo King to iatrogenic Cushing syndrome and adrenal insufficiency. A third report documented exogenous Cushing syndrome and a hip fracture in a patient using Artri King. These are not theoretical risks. They are documented injuries in real patients.
FDA enforcement from lab tests to retailer warning letters
The FDA’s response has spanned multiple enforcement tools. The agency maintains a continuously updated hub listing pain and arthritis supplements with hidden ingredients, a catalog that has grown over several years. Beyond individual product alerts, the agency issued a broader drug alert stating that lab analyses found undeclared dexamethasone, diclofenac sodium, and methocarbamol in certain Artri and Ortiga products, and that more than 30 additional consumers experienced serious health effects.
The FDA also traced the supply chain to two of the largest retailers in the country. The agency purchased Artri and Ortiga products through Amazon and confirmed via laboratory analysis that sampled items contained diclofenac not listed on the labels, a finding detailed in a warning letter sent to Amazon in October 2022. A parallel warning letter went to Walmart after the FDA purchased an Artri product through Walmart’s website and confirmed it also contained undeclared diclofenac. These letters put both companies on notice that they were selling unapproved new drugs, not lawful dietary supplements.
On the import side, an FDA import alert lists Artri King Reforzado con Ortiga y Omega 3 for detention without physical examination, citing lab-confirmed undeclared diclofenac and dexamethasone. That designation allows field staff to stop shipments at the border rather than relying on case-by-case testing. The FDA’s Center for Drug Evaluation and Research highlighted these enforcement actions on Artri and Ortiga products in its Office of Compliance annual report for fiscal year 2022, framing them as examples of efforts to address medication health fraud.
Several of these products are marketed in Spanish, and the FDA has issued Spanish-language public notifications for items like RM Joe, where lab analysis confirmed undeclared dexamethasone phosphate and diclofenac. That detail matters because it indicates these supplements are disproportionately reaching Spanish-speaking communities, many of whom rely on safety-net health systems where clinicians may not immediately suspect steroid exposure from a supplement. When patients present with unexplained weight gain, facial rounding, or severe fatigue, language barriers and incomplete medication histories can further delay recognition that a “natural” arthritis pill is the underlying cause.
Gaps in tracking and what consumers should do now
Despite the mounting evidence, there is no centralized public database linking suspected adverse events from hidden-steroid supplements with specific brands, lot numbers, and retail outlets. The FDA’s MedWatch system collects voluntary reports, but underreporting is almost certain: patients may not realize a supplement is to blame, and clinicians may not think to ask about products purchased at flea markets, small neighborhood stores, or online marketplaces. Without more complete reporting, regulators are left to piece together patterns from scattered case reports, import testing, and sporadic lab analyses.
That gap makes individual vigilance even more important. Consumers who have used Artri, Ortiga, Curcuflex, Yeicob Acido Hialuronico, RM Joe, or similar joint-pain supplements should not stop abruptly on their own. Instead, they should bring the product bottles to a clinician and ask whether a gradual taper or endocrine evaluation is needed, especially if they have symptoms such as fatigue, dizziness, muscle weakness, new fractures, or dramatic changes in weight or blood sugar. Health professionals may need to check morning cortisol levels or perform additional testing to assess adrenal function.
For people considering arthritis supplements, a few practical steps can reduce risk. Be wary of products that promise rapid, dramatic pain relief, particularly if they are marketed primarily through social media, informal channels, or in non-English packaging without clear manufacturer information. Check the FDA’s list of supplements flagged for hidden drugs before buying new pain-relief capsules or tablets. If a product appears on that list, treat it as a prescription medication taken without medical oversight, not as a harmless vitamin.
Clinicians can also adjust their routines in light of these findings. When evaluating patients with unexplained Cushingoid features, adrenal insufficiency, or refractory joint pain, a detailed supplement history should be as routine as asking about prescription drugs. For Spanish-speaking patients and others who may rely on imported or informal-market remedies, having bilingual staff or interpreters probe specifically about “pastillas para la artritis” or “productos naturales” can uncover exposures that would otherwise be missed.
Ultimately, the FDA’s lab results and case reports point to a systemic problem: a segment of the supplement market is functioning as a shadow prescription-drug channel, delivering potent steroids and NSAIDs without the safeguards that normally accompany them. Until surveillance catches up and enforcement closes those gaps, the safest assumption for consumers is that any arthritis supplement promising outsized relief could carry hidden risks-risks that only come into focus when someone ends up in the hospital.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
